Pharmaceuticals New Zealand

New Zealand Direct-to-Consumer Genetic Testing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

New Zealand Direct-to-Consumer Genetic Testing Market Industry Trends and Forecast to 2034: Segmented by (Test, Channel, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

New Zealand · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $25.4 Mn Placeholder estimate
Estimate 2025 $28.6 Mn 1.1% of the global market
Projected 2034 $82.6 Mn 188.7% Adds $54.0 Mn over 9 forecast years
CAGR 2025–2034 12.5% Faster than 69% of 163 Pharmaceuticals markets here
Key players 5 Companies profiled
  • New Zealand is 1.14% of the global market.
  • In APAC, the largest is China at $210.6 Mn.
  • Fastest growing: India at 14.7% a year.
  • New Zealand ranks 5th of 10 by size in APAC.

Market size projection

New Zealand

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$54.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Direct-to-Consumer Genetic Testing Market market size by year, New Zealand
YearMarket sizeChange that yearSince 2025
2024 (estimate) $25.4 Mn — —
2025 (base) $28.6 Mn +$3.2 Mn —
2026 (forecast) $32.2 Mn +$3.6 Mn +12.5%
2027 (forecast) $36.2 Mn +$4.0 Mn +26.6%
2028 (forecast) $40.7 Mn +$4.5 Mn +42.4%
2029 (forecast) $45.8 Mn +$5.1 Mn +60.2%
2030 (forecast) $51.5 Mn +$5.7 Mn +80.2%
2031 (forecast) $58.0 Mn +$6.4 Mn +102.7%
2032 (forecast) $65.2 Mn +$7.2 Mn +128.1%
2033 (forecast) $73.4 Mn +$8.2 Mn +156.6%
2034 (forecast) $82.6 Mn +$9.2 Mn +188.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

New Zealand Direct-to-Consumer Genetic Testing Market Analysis at a glance
Market size, 2025$28.6 Mn placeholder estimate
Forecast, 2034$82.6 Mn placeholder estimate
Growth (CAGR), 2025–203412.5% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTest and channel (see all)
Key players23andMe, Ancestry, MyHeritage, Nebula Genomics, Inc., Color Health (see all)
Regulator in New ZealandMedsafeSource: Medsafe. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The New Zealand Direct-to-Consumer Genetic Testing Market Analysis Executive Summary

Direct-to-consumer genetic tests are bought online by individuals to learn about ancestry, traits and some health risks from a saliva sample.

Key segments of the direct-to-Consumer Genetic Testing market include test (Ancestry, Health Risk and Carrier Status) and channel (Online and Retail).

Bar chart: New Zealand Direct-to-Consumer Genetic Testing market size, 2024–2034, placeholder estimates. $25.4 Mn in 2024, $28.6 Mn in 2025 and $82.6 Mn in 2034, 12.5% CAGR.
New Zealand Direct-to-Consumer Genetic Testing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

New Zealand Direct-to-Consumer Genetic Testing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the direct-to-Consumer Genetic Testing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the direct-to-Consumer Genetic Testing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the direct-to-Consumer Genetic Testing market.

Competitive Landscape for Direct-to-Consumer Genetic Testing Market in New Zealand

The direct-to-Consumer Genetic Testing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Direct-to-Consumer Genetic Testing Market in New Zealand

Direct-to-Consumer Genetic Testing in New Zealand: rules and payment

Medsafe, part of the Ministry of Health, approves medicines before they can be sold.⁠[1] Pharmac decides which medicines and medical devices the public health system pays for.⁠[2]

[1] Medsafe. Checked 14 Nov 2026.

[2] Pharmac. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for direct-to-Consumer Genetic Testing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in New Zealand.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Direct-to-Consumer Genetic Testing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Direct-to-Consumer Genetic Testing in context

New Zealand compared

  • Health spending per person: 5,022 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 17 countries we cover in APAC.[1]
  • Doctors: 3.61 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 2nd highest of the 17 countries we cover in APAC.[2]
  • People aged 65 and over: 17.6% of people (2025). World: 10.4% of people (2025). 5th highest of the 18 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 20 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 20 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 21 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Direct-to-Consumer Genetic Testing market in New Zealand?
Placeholder estimate: about $28.6 Mn in 2025, rising to about $82.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Direct-to-Consumer Genetic Testing market in New Zealand growing?
Placeholder estimate: about 12.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Direct-to-Consumer Genetic Testing market report cover?
The report splits the market by test (Ancestry, Health Risk, Carrier Status, Nutrigenomics) and channel (Online, Retail).
Who are the key players in the Direct-to-Consumer Genetic Testing market?
Key players include 23andMe, Ancestry, MyHeritage, Nebula Genomics, Inc. and Color Health.
What is driving the Direct-to-Consumer Genetic Testing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the direct-to-Consumer Genetic Testing market.
Who regulates Direct-to-Consumer Genetic Testing in New Zealand?
Medsafe, part of the Ministry of Health, approves medicines before they can be sold. Source: Medsafe. Checked 14 Nov 2026.
How is healthcare paid for in New Zealand?
Pharmac decides which medicines and medical devices the public health system pays for. Source: Pharmac. Checked 14 Nov 2026.
How much research is published on Direct-to-Consumer Genetic Testing?
PubMed lists 144 papers on Direct-to-Consumer Genetic Testing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in New Zealand

See all

Related on genomics

See the topic